Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).

被引：0
|
作者：
Brahmer, Julie R.
Horn, Leora
Antonia, Scott
Spigel, David R.
Gandhi, Leena
Sequist, Lecia V.
Wigginton, Jon
McDonald, Dan
Kollia, Georgia
Gupta, Ashok Kumar
Gettinger, Scott N.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] SCRI Tennessee Oncol PLLC, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[7] Bristol Myers Squibb Co, Princeton, NJ USA
[8] Yale Univ, Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7509
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients (Pts) with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Brahmer, J. R.
    Horn, L.
    Antonia, S. J.
    Spigel, D.
    Gandhi, L.
    Sequist, L.
    Wigginton, J. M.
    Kollia, G.
    Gupta, A.
    Gettinger, S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204
  • [2] Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).
    Hodi, F. Stephen
    Sznol, Mario
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Wigginton, Jon
    McDonald, Dan
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response
    Topalian, Suzanne Louise
    Brahmer, Julie R.
    Hodi, F. Stephen
    McDermott, David F.
    Smith, David C.
    Gettinger, Scott N.
    Taube, Janis M.
    Drake, Charles G.
    Pardoll, Drew M.
    Antonia, Scott
    Spigel, David R.
    Atkins, Michael B.
    Lawrence, Donald P.
    McDonald, Dan
    Jure-Kunkel, Maria
    Korman, Alan
    Kollia, Georgia
    Gupta, Ashok Kumar
    Wigginton, Jon
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] CLINICAL ACTIVITY AND SAFETY OF ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Gettinger, S.
    Horn, L.
    Antonia, S. J.
    Spigel, D.
    Gandhi, L.
    Sequist, L. V.
    Wigginton, J. M.
    Kollia, G.
    Gupta, A.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2012, 23 : 405 - 406
  • [5] Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC)
    McDermott, David F.
    Drake, Charles G.
    Sznol, Mario
    Choueiri, Toni K.
    Powderly, John
    Smith, David C.
    Wigginton, Jon
    McDonald, Dan
    Kollia, Georgia
    Gupta, Ashok Kumar
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies
    Sznol, M.
    Powderly, J. D.
    Smith, D. C.
    Brahmer, J. R.
    Drake, C. G.
    McDermott, D. F.
    Lawrence, D. P.
    Wolchok, J. D.
    Topalian, S. L.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] CLINICAL ACTIVITY AND SAFETY OF ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Sosman, J.
    Sznol, M.
    McDermott, D. F.
    Carvajal, R.
    Lawrence, D. P.
    Topalian, S. L.
    Wigginton, J. M.
    Kollia, G.
    Gupta, A.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 361 - 361
  • [8] ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: CLINICAL ACTIVITY, SAFETY, AND MOLECULAR MARKERS
    Topalian, S. L.
    Brahmer, J. R.
    Hodi, F. S.
    McDermott, D. F.
    Smith, D. C.
    Gettinger, S.
    Taube, J. M.
    Gupta, A.
    Wigginton, J. M.
    Sznol, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 157 - 157
  • [9] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.
    Brahmer, Julie R.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott Joseph
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca Suk
    Carvajal, Richard D.
    Jackman, David Michael
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne Louise
    Hodi, F. Stephen
    Sznol, Mario
    Harbison, Christopher
    Kollia, Georgia
    Gupta, Ashok Kumar
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies
    McDermott, D. F.
    Drake, C. G.
    Sznol, M.
    Sosman, J. A.
    Smith, D. C.
    Powderly, J. D.
    Feltquate, D. M.
    Kollia, G.
    Gupta, A. K.
    Wigginton, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345